Farooq Sheikh, MD
Advanced Heart Failure and Transplant Cardiology · Washington, DCNPI 1205989068
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (48.0%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Abbott at 51.8% of the total. 2025 is the largest year on record at $33,812, 2.1 times the $15,833 reported in 2019.
Across 299 payments — averaging $358.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$56K
- Alnylam Pharmaceuticals Inc.$22K
- Pfizer$6K
- AstraZeneca$5K
- Akcea Therapeutics, Inc.$4K
- Astrazeneca UK Limited$3K
- plus $12K from 13 others
Across 215 payments — averaging $5741.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alnylam Pharmaceuticals Inc.$572K
- Abbott$443K
- AstraZeneca$111K
- Ionis Pharmaceuticals, Inc.$80K
- Eidos Therapeutics, Inc.$17K
- Xvivo Perfusion Inc.$9K
- plus $4K from 3 others
What the payments were for
- Consulting fees$51,40548%
- Speaking & faculty fees$18,63017%
- Travel & lodging$21,44320%
- Food & beverage$15,50714%
- Education$950%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 201 | $55,510 |
| Alnylam Pharmaceuticals Inc. | 28 | $22,338 |
| Pfizer | 12 | $5,644 |
| AstraZeneca | 4 | $4,511 |
| Akcea Therapeutics, Inc. | 6 | $3,579 |
| Astrazeneca UK Limited | 1 | $3,222 |
| Medtronic | 10 | $2,433 |
| Xvivo Perfusion Inc. | 1 | $2,250 |
| Procyrion, Inc. | 1 | $2,100 |
| Cvrx, Inc. | 11 | $1,845 |
| Bridgebio Pharma, Inc. | 2 | $1,830 |
| Abiomed | 13 | $883 |
| Paragonix Technologies, Inc. | 1 | $337 |
| Ancora Heart, Inc. | 1 | $279 |
| Novo Nordisk | 1 | $121 |
| Sanofi | 1 | $95 |
| Amgen | 3 | $77 |
| Daxor Corporation | 1 | $19 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$33,639
- CARDIOMEMS$11,115
- WAINUA$7,518
- HeartMate 3 Left Ventricular Dev$6,035
- VYNDAMAX$5,120
- AMVUTTRA$3,772
- TEGSEDI$3,375
- ONPATTRO$3,266
- XVIVO Perfusion System (XPS)$2,250
- HeartWare HVAD$2,136
- AORTIX SYSTEM$2,100
- Attruby$1,830
- Barostim Neo System$1,512
- FreeStyle Libre Pro$1,191
- Impella$557
- HeartMate 3 Left Ventricular Assist Device$366
- Paragonix SherpaPak Cardiac Transport System$337
- SherpaCool Box$337
- CTS Canister Box$337
- AccuCinch$279
How this compares
Too few advanced heart failure and transplant cardiology providers in District of Columbiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 233 | $6,128,798 |
| VyndaqelTafamidis Meglumine | 28 | $603,762 |
| EntrestoSacubitril/Valsartan | 92 | $145,158 |
| EliquisApixaban | 71 | $97,035 |
| FarxigaDapagliflozin Propanediol | 100 | $90,320 |
| JardianceEmpagliflozin | 59 | $78,038 |
| Eplerenone | 28 | $2,302 |
| Mycophenolate Mofetil | 16 | $2,280 |
| Potassium Chloride | 26 | $2,242 |
| Torsemide | 46 | $2,202 |
| Spironolactone | 126 | $1,069 |
| Metoprolol Succinate | 49 | $970 |
| Carvedilol | 80 | $740 |
| Atorvastatin Calcium | 66 | $657 |
| Rosuvastatin Calcium | 20 | $322 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Vyndaqel, Eliquis | $5,644 | $6,829,594332 claims |
| AstraZenecaFarxiga | $4,511 | $90,320100 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in District of Columbiaon file to place this against a meaningful peer group, so we don't.
Other advanced heart failure and transplant cardiology in Washington
- Gurusher PanjrathWashington$426K
- Shaline RaoWashington$120K
- Mrinalini KrishnanWashington$111K
- Tania VoraWashington$15K
- Samer NajjarWashington$12K
- Mark HofmeyerWashington$10K
- Ul WeenaWashington$4K
- Phillip LamWashington$4K
- Ahmed KhanWashington$957
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.